We conducted a double-blind, placebo-controlled efficacy trial of the live attenuated Oka/Merck varicella vaccine among 956 children between the ages of 1 and 14 years, with a negative clinical history of varicella. Of the 914 children who were serologically confirmed to be susceptible to varicella, 468 received vaccine and 446 received placebo. The vaccine produced few clinical reactions and was well tolerated. There was no clinical evidence of viral spread from vaccinated children to sibling controls. Approximately eight weeks after vaccination, 94 per cent of the initially seronegative children who received vaccine had detectable antibody to varicella. During the nine-month surveillance period, 39 clinically diagnosed cases of varicella, 38 of which were confirmed by laboratory tests, occurred among study participants. All 39 cases occurred in placebo recipients; no child who received vaccine contracted varicella. The vaccine was 100 per cent efficacious in preventing varicella in this population of healthy children (P less than 10(-9).
This article has been cited by other articles:
Jean-Philippe, P., Freedman, A., Chang, M. W., Steinberg, S. P., Gershon, A. A., LaRussa, P. S., Borkowsky, W.
(2007). Severe Varicella Caused by Varicella-Vaccine Strain in a Child With Significant T-Cell Dysfunction. Pediatrics
120: e1345-e1349
[Abstract][Full Text]
Committee on Infectious Diseases,
(2007). Prevention of Varicella: Recommendations for Use of Varicella Vaccines in Children, Including a Recommendation for a Routine 2-Dose Varicella Immunization Schedule. Pediatrics
120: 221-231
[Abstract][Full Text]
Parker, S. P., Quinlivan, M., Taha, Y., Breuer, J.
(2006). Genotyping of Varicella-Zoster Virus and the Discrimination of Oka Vaccine Strains by TaqMan Real-Time PCR.. J. Clin. Microbiol.
44: 3911-3914
[Abstract][Full Text]
Hambleton, S., Gershon, A. A.
(2005). Preventing Varicella-Zoster Disease. Clin. Microbiol. Rev.
18: 70-80
[Abstract][Full Text]
McClellan, J. S., Tibbetts, S. A., Gangappa, S., Brett, K. A., Virgin, H. W. IV
(2004). Critical Role of CD4 T Cells in an Antibody-Independent Mechanism of Vaccination against Gammaherpesvirus Latency. J. Virol.
78: 6836-6845
[Abstract][Full Text]
Tibbetts, S. A., McClellan, J. S., Gangappa, S., Speck, S. H., Virgin, H. W. IV
(2003). Effective Vaccination against Long-Term Gammaherpesvirus Latency. J. Virol.
77: 2522-2529
[Abstract][Full Text]
Breuer, J.
(2003). Live attenuated vaccine for the prevention of varicella-zoster virus infection: does it work, is it safe and do we really need it in the UK?. J Med Microbiol
52: 1-3
[Full Text]
Galil, K., Lee, B., Strine, T., Carraher, C., Baughman, A. L., Eaton, M., Montero, J., Seward, J.
(2002). Outbreak of Varicella at a Day-Care Center despite Vaccination. NEJM
347: 1909-1915
[Abstract][Full Text]
Gershon, A. A.
(2002). Varicella Vaccine -- Are Two Doses Better Than One?. NEJM
347: 1962-1963
[Full Text]
Wills, M R, Carmichael, A J, Sissons, J G P
(2002). Vaccines against persistent DNA virus infections. Br Med Bull
62: 125-138
[Abstract][Full Text]
Wallington, T., Weir, E.
(2002). Varicella control and vaccine coverage: issues and challenges. CMAJ
166: 631-632
[Full Text]
Dennehy, P. H.
(2001). Active Immunization in the United States: Developments over the Past Decade. Clin. Microbiol. Rev.
14: 872-908
[Abstract][Full Text]
Breuer, J
(2001). Vaccination to prevent varicella and shingles. J. Clin. Pathol.
54: 743-747
[Abstract][Full Text]
Skull, S A, Wang, E E L
(2001). Current topic: Varicella vaccination{---}a critical review of the evidence. Arch. Dis. Child.
85: 83-90
[Full Text]
(2001). Varicella vaccination: Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ
164: 1888-1889
[Full Text]
Farquhar, D.
(2001). Varicella vaccine in clinical practice. CMAJ
164: 1485-1485
[Full Text]
Clements, D. A., Zaref, J. I., Bland, C. L., Walter, E. B., Coplan, P. M.
(2001). Partial Uptake of Varicella Vaccine and the Epidemiological Effect on Varicella Disease in 11 Day-Care Centers in North Carolina. Arch Pediatr Adolesc Med
155: 455-461
[Abstract][Full Text]
Vazquez, M., LaRussa, P. S., Gershon, A. A., Steinberg, S. P., Freudigman, K., Shapiro, E. D.
(2001). The Effectiveness of the Varicella Vaccine in Clinical Practice. NEJM
344: 955-960
[Abstract][Full Text]
Wise, R. P., Salive, M. E., Braun, M. M., Mootrey, G. T., Seward, J. F., Rider, L. G., Krause, P. R.
(2000). Postlicensure Safety Surveillance for Varicella Vaccine. JAMA
284: 1271-1279
[Abstract][Full Text]
GERSHON, A.
(1998). Varicella: to vaccinate or not to vaccinate?. Arch. Dis. Child.
79: 470-471
[Full Text]
Lim, Y J, Chew, F T, Tan, A Y S, Lee, B W
(1998). Risk factors for breakthrough varicella in healthy children. Arch. Dis. Child.
79: 478-480
[Abstract][Full Text]
